LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Eurofins Launches New Ultra-Fast Extraction-Free RT-PCR Method and Upgrades its SARS-CoV-2 RT-PCR Assay

By LabMedica International staff writers
Posted on 17 Feb 2021
Print article
Illustration
Illustration
Eurofins (Luxembourg) has launched a new ultra-fast extraction-free RT-PCR method and upgraded its RT-PCR assay for use with pharynx gargle and saliva sample matrices.

The GSD NovaPrime SARS-CoV-2 Direct RT-PCR from Eurofins is intended for the qualitative detection of SARS-CoV-2 from human nasopharyngeal swabs, eluted directly into demonized water without an additional RNA extraction process (extraction-free). Increase of global SARS-CoV-2 testing worldwide has posed new challenges to laboratories in nearly all countries. More than ever, there is a critical need for rapid molecular solutions to increase testing capacity, and provide accurate and faster results. Removing the RNA extraction step helps to meet this challenge, by increasing the number of laboratories that can perform these tests, allowing more tests to be performed and reducing the cost, labor, and time required to carry out very sensitive PCR tests.

The GSD NovaPrime SARS-CoV-2 Direct RT-PCR is CE marked and has been validated as an extraction-free method. This new workflow shortens the complete turnaround time of the test, providing results in approximately one hour from sample to result without compromising the high accuracy of PCR testing, and allowing for a higher processing capacity. The GSD NovaPrime SARS-CoV-2 (COVID-19) has now been successfully validated for pharynx gargle and saliva samples. These new matrices constitute an easy-to-use sampling method that is particularly useful for self-sampling applications and are suitable for children. The test is a highly sensitive multiplex real-time PCR assay intended for the qualitative determination of SARS-CoV-2 genomic RNA in respiratory samples. The assay simultaneously detects two target sequences in the N gene.


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Complement 3 (C3) Test
GPP-100 C3 Kit
New
Gold Member
COVID-19 Rapid Test
AQ+ COVID-19 Ag Rapid Test

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: The AI predictive model identifies the most potent cancer killing immune cells for use in immunotherapies (Photo courtesy of Shutterstock)

AI Predicts Tumor-Killing Cells with High Accuracy

Cellular immunotherapy involves extracting immune cells from a patient's tumor, potentially enhancing their cancer-fighting capabilities through engineering, and then expanding and reintroducing them into the body.... Read more

Microbiology

view channel
Image: The T-SPOT.TB test is now paired with the Auto-Pure 2400 liquid handling platform for accurate TB testing (Photo courtesy of Shutterstock)

Integrated Solution Ushers New Era of Automated Tuberculosis Testing

Tuberculosis (TB) is responsible for 1.3 million deaths every year, positioning it as one of the top killers globally due to a single infectious agent. In 2022, around 10.6 million people were diagnosed... Read more